目的 统计青岛市精神卫生中心2019—2022年抗抑郁药使用情况并分析变化趋势，以期为临床合理用药提供参考。方法 采用回顾性分析方法统计青岛市精神卫生中心信息系统中2019年1月—2022年12月抗抑郁药的销售金额，并计算用药频度（DDDs）、限定日费用（DDC）以及药品排序比（B/A）。结果 2019—2022年，医院抗抑郁药销售金额基本稳定，艾司西酞普兰和度洛西汀的销售金额排序始终居于前2位；抗抑郁药的DDDs总体呈增长趋势，艾司西酞普兰的DDDs排序始终居于首位；抗抑郁药的DDC及排序基本稳定，其中曲唑酮、安非他酮、度洛西汀的DDC较高，居于前3位；阿米替林、安非他酮、多塞平、氟伏沙明、氟西汀、氯米帕明、西酞普兰的B/A值接近于1.0。结论 青岛市精神卫生中心抗抑郁药的使用基本合理，后期仍需加强监督管理，以保证患者合理用药。

Objective To make statistics on the use of antidepressants in Qingdao Mental Health Center from 2019 to 2022 and analyze the trend of change, so as to provide reference for clinical rational drug use. Methods The sales amount of antidepressants from January 2019 to December 2022 in the information system of Qingdao Mental Health Center was analyzed retrospectively, and the DDDs, DDC, and B/A were calculated. Results From 2019 to 2022, the consumption sum of antidepressants in the hospital was basically stable, and the consumption sum of escitalopram and duloxetine always ranked first and second. The DDDs of antidepressants showed an overall increasing trend, and the DDDs of escitalopram always ranked first. The DDC and order of antidepressants were basically stable, among which the DDC of trazodone, bupropion, and duloxetine were higher, ranking the first 3. The B/A values of amitriptyline, bupropion, doxepin, fluvoxamine, fluoxetine, clomipramine, and citalopram were close to 1.0. Conclusion The use of antidepressants in Qingdao Mental Health Center was basically reasonable, and supervision and management should be strengthened in the later stage to ensure the rational drug use by patients.

R971